Please login to the form below

Not currently logged in
Email:
Password:

Ariad Pharma

This page shows the latest Ariad Pharma news and features for those working in and with pharma, biotech and healthcare.

Angelini to market Ariad’s Iclusig in Eastern Europe

Angelini to market Ariad’s Iclusig in Eastern Europe

Angelini to market Ariad’ s Iclusig in Eastern Europe. Comes after leukaemia drug passes EMA safety review. ... US pharma company Ariad Pharmaceuticals has licensed its cancer drug Iclusig to Italy-based firm Angelini Pharma to market in 23 Eastern

Latest news

  • Pfizer faces NICE rejection for cancer drug Bosulif Pfizer faces NICE rejection for cancer drug Bosulif

    In April 2013 an article in the journal Blood saw 20 physicians specialising in CML treatment call for price reductions for CML drugs, claiming that Bosulif, Ariad Pharma's Iclusig (ponatinib) ... So far this pressure has been focused on the US, however

  • Leukaemia drug prices Leukaemia drug prices "unsustainable" say cancer experts

    The experts single out three new drugs for CML approved by the FDA last year - Pfizer's Bosulif (bosutinib), Ariad Pharma's Iclusig (ponatinib) and Teva's Synribo (omacetaxine) - which they

  • EU recommendations for Gilead, Ariad and Baxter drugs EU recommendations for Gilead, Ariad and Baxter drugs

    Gilead Sciences, Ariad Pharma and Baxter have all received backing from the European Medicines Agency (EMA) to market new treatments. ... Iclusig approved to treat leukaemia. The CHMP also gave a positive opinion to Ariad Pharma for the use of Iclusig

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics